Oxford Biomedica plc (OTCPK:OXBDF) Q4 2024 Earnings Conference Call April 9, 2025 8:00 AM ET
Company Participants
Frank Mathias – Chief Executive Officer
Sebastien Ribault – Chief Business Officer
Lucy Crabtree – Chief Financial Officer
Conference Call Participants
Charles Weston – RBC Capital Markets
Andy Smith – Equity Development
John Priestner – JPMorgan
Jens Lindqvist – Investec
Rick Bienkowski – Cantor Fitzgerald
Frank Mathias
So, good afternoon to everyone here in London, and also good morning to those who are joining us from overseas. Thank you for attending this call today, our analyst briefing for our 2024 Preliminary Results. It’s great to see so many people here in the room, known faces. Thank you for joining. But we have also a few people joining virtually. So, hello to everyone again.
Presenting with me today, we have our Chief Financial Officer, Dr. Lucy Crabtree, who started to join us in September last year and has already made a significant impact during this short period. I’m also pleased to welcome our Chief Business Officer, Dr. Sebastien Ribault. You are known, I believe, well here, and a lot of you are familiar with him.
So disclaimer. Before we dive in, let’s start with our agenda for today. As you can see, we will start with an overview of the key achievements across the business, highlighting what sets up OXB apart from our peers and how our differentiated pure play CDMO strategy in cell and gene therapy continues to drive our success. I will then hand over to Sebastian to provide us an update on the strong momentum we are seeing on the commercial side. And then, Lucy will take us through our financial performance before handing back to me to wrap up ahead of the Q&A session.
This is a nice slide. I would
Credit: Source link
